反応式
[F:1][C:2]1[CH:7]=[CH:6][C:5]([C@H:8]([CH2:18][C:19]([N:21]2[CH2:26][CH2:25][O:24][CH2:23][CH2:22]2)=[O:20])[C:9]([NH:11][C@H:12]([CH2:16][OH:17])[CH:13]([CH3:15])[CH3:14])=[O:10])=[CH:4][CH:3]=1.CC(OI1(OC(C)=O)(OC(C)=O)OC(=O)C2C=CC=CC1=2)=O>C(Cl)Cl.CCOC(C)=O>[F:1][C:2]1[CH:7]=[CH:6][C:5]([C@H:8]([CH2:18][C:19]([N:21]2[CH2:26][CH2:25][O:24][CH2:23][CH2:22]2)=[O:20])[C:9]([NH:11][C@H:12]([CH:16]=[O:17])[CH:13]([CH3:14])[CH3:15])=[O:10])=[CH:4][CH:3]=1参加物
5
反応物 2
生成物 1
試薬・触媒・溶媒 2
実験手順
2-(S)-(4-Fluoro-phenyl)-N-(1-(S)-hydroxymethyl-2-methyl-propyl)-4-morpholin-4-yl-4-oxo-butyramide (2.31 g, 6.30 mmol, 1.0 eq.) was dissolved in CH2Cl2 (32 mL) and stirred at room temperature. Dess-Martin Periodinane (2.67 g, 6.30 mmol, 1.0 eq.) was added in one portion and the reaction is monitored by LC/MS and TLC. Upon completion, the reaction is diluted with EtOAc (200 mL) and extracted with 1M Na2S2O3 (100 mL), NaHCO3 (100 mL) and brine. The organic phase is dried over MgSO4, filtered and evaporated to provide 2-(S)-(4-Fluoro-phenyl)-N-(1-(S)-formyl-2-methyl-propyl)-4-morpholin-4-yl-4-oxo-butyramide (1.41 g, 3.89 mmol, 62%) and used directly in the next step. HPLC-MS calcd. for C19H25FN2O4 (M+H+) 365.2, found 365.4.
後処理
- extractionextracted with 1M Na2S2O3 (100 mL), NaHCO3 (100 mL) and brine
- dry with materialThe organic phase is dried over MgSO4
- filtrationfiltered
- customevaporated
出典と根拠
- ORDレコード
- ord-ed10a5a388014fa48116a42541cc0bf6
- 出典データセット
- uspto-grants-2009_03
- 特許番号
- US07501408B2
関連ノート
読み込み中…